510 related articles for article (PubMed ID: 6910481)
1. Complement receptor is an inhibitor of the complement cascade.
Iida K; Nussenzweig V
J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
[TBL] [Abstract][Full Text] [Related]
2. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
3. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
Medof ME; Nussenzweig V
J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
6. Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells.
Kinoshita T; Medof ME; Hong K; Nussenzweig V
J Exp Med; 1986 Nov; 164(5):1377-88. PubMed ID: 2430040
[TBL] [Abstract][Full Text] [Related]
7. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
8. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
9. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
[TBL] [Abstract][Full Text] [Related]
11. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
12. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
13. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
14. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
16. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.
Klickstein LB; Bartow TJ; Miletic V; Rabson LD; Smith JA; Fearon DT
J Exp Med; 1988 Nov; 168(5):1699-717. PubMed ID: 2972794
[TBL] [Abstract][Full Text] [Related]
17. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
Gigli I; Sorvillo J; Halbwachs-Mecarelli L
J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
19. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway.
Scesney SM; Makrides SC; Gosselin ML; Ford PJ; Andrews BM; Hayman EG; Marsh HC
Eur J Immunol; 1996 Aug; 26(8):1729-35. PubMed ID: 8765013
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
